Aaron Berger, MD, discusses testosterone recovery after prostate cancer therapy interruption and its implications for quality of life, PSA kinetics, and treatment decisions.
|Videos|December 24, 2020
Patient counseling for mesh mid-urethral sling surgery: Provide options, set expectations
Author(s)Urology Times staff
“Listen. Be emphatic. Be transparent,” Pansy Uberoi, MD, MPH, advises in this interview.
Advertisement
In this interview, Una Lee, MD, and Pansy Uberoi, MD, MPH, discuss how clinicians can improve patients’ experiences with mesh mid-urethral sling surgery. Lee and Uberoi were study authors of, “Listening to women: a qualitative analysis of experiences after complications from mesh mid-urethral sling surgery,” which was published in Urology. Lee is a urologist at Virginia Mason Medical Center, Seattle, Washington and assistant clinical professor of urology at the University of Washington, Seattle, and Uberoi is a fellow in female pelvic medicine and reconstructive surgery at Virginia Mason Medical Center.
Advertisement
Related to this article
Kiran Sury, MD, discusses patient selection, durability, and adverse events with ProACT for male stress urinary incontinence.
Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.
Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.
Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.
William Huang, MD, discusses histotripsy for renal tumors, the #HOPE4KIDNEY trial, and the technology’s potential to preserve kidney function.
Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
Elie Kaplan-Marans, MD, discusses geographic disparities in reproductive urology access and how workforce gaps may affect comprehensive infertility evaluations.
Advertisement
Advertisement
Trending on Urology Times
1
Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life
2
FDA approves durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC
3
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
4
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
5